Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.23.4
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Nov. 30, 2023
Nov. 30, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)    
Revenue $ 151,278 $ 97,735
Cost of goods sold 4,822 15,795
Gross profit 146,456 81,940
Operating expenses    
Research and development 574,491 829,489
General and administrative 711,107 947,870
Total operating expenses 1,285,598 1,777,359
Loss from operations (1,139,142) (1,695,419)
Other income (loss)    
Interest income 7,319 3,741
Unrealized loss on marketable securities (53,215) (77,628)
Total other income (loss) (45,896) (73,887)
Net loss for the period (1,185,038) (1,769,306)
Less: Net loss attributable to non-controlling interest (5,715) (13,362)
Net loss attributable to Lexaria shareholders (1,179,323) (1,755,944)
Other comprehensive income    
Foreign currency translation adjustment (4,372) 0
Total comprehensive loss $ (1,174,951) $ (1,755,944)
Basic and diluted loss per share $ (0.13) $ (0.30)
Weighted average number of common shares outstanding    
- Basic and diluted 9,051,531 5,950,998